リーダーシップ

Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX^® and Neumega^®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol^®/Glucotrol XL^®, Zoloft^®, and Cardura^®. Ms. Dawes also serves on the board of directors of two publicly traded companies: PaxMedica Therapeutics and Medicenna Therapeutics Corp, one private company, Vaccitech Limited, and on one not-for-profit company, Medicines 360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.

Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 25 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen Inc. (“Biogen”) for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. In addition to Repligen, Mr. Barthelemy also serves on the board of directors of three publicly traded companies; Fluidigm Corporation, Twist Bioscience and 908 Devices Inc., and one privately held company; Biocare Medical LLC. He also serves as an advisor to Warburg Pincus, a private equity firm. Mr. Barthelemy received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.

Carrie Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 24 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as Senior Vice President, Advanced Diagnostics at Quest Diagnostics, which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In her role at Quest Diagnostics, Ms. Eglinton Manner is responsible for growing the company’s nearly $2 billion genetic and molecular diagnostics portfolio, through innovation in specialty genetic offerings and services, productivity programs, key strategic alliances, and acquisitions. In addition to joining the Repligen board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and transforming health in underserved communities. Ms. Eglinton Manner holds a B.S. in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Company’s Board include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President, Product and Technology Development at Biogen. He has held numerous other roles of increasing responsibility within Biogen, which he joined in 1996, including six years as Vice President of Biopharmaceutical Development, where he led a 300-member team responsible for cell line, cell culture, purification and device development. Earlier in Dr. Mhatre’s career at Biogen, he focused on building out analytical development and technical services. Prior to Biogen, Dr. Mhatre led the purification and applications group at Applied BioSystems (formerly Perspective Biosystems). Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Company’s Board of Directors include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows.

Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc., a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies; medical technology company Neuronetics, Inc. and life science company G1 Therapeutics, Inc. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board of Directors include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.

Thomas F. Ryan Jr. has served as a director of Repligen since September 2003. Mr. Ryan is currently an investor in various private companies. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a B.A. from Boston College and is a graduate of the Boston Latin School. Mr. Ryan is a director for the New York State Independent System Operator and a director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and investment banking.

Richard D. Braatzは、マサチューセッツ工科大学（MIT）のEdwin R. Gilliland教授で、高度な製造システムのプロセスデータ解析、設計、制御の研究を行っています。カリフォルニア工科大学で修士号と博士号を取得し、イリノイ大学アーバナ・シャンペーン校のミレニアムチェアと教授、ハーバード大学の客員研究員を経て、マサチューセッツ工科大学（MIT）に移りました。Merck社、Novartis社、Pfizer社、Amgen社、Biogen社、Bristol-Myers Squibb社など、30社以上の企業とコンサルティングやコラボレーションを行ってきました。全米工学アカデミー会員です。

Charles L. Cooneyは、Robert T. Haslam（1911）化学・生化学工学教授、マサチューセッツ工科大学化学工学科名誉教授、マサチューセッツ工科大学デシュパンデ技術革新センター名誉所長です。ペンシルバニア大学で化学工学の理学士号を取得し、MITで生化学工学のSM（科学マスター）と博士号を取得。MITの教員としてキャリアを積んできました。プロセス設計、アップストリームおよびダウンストリームバイオプロセス開発、医薬品・バイオ製品の製造を得意としています。Cooney教授は、さまざまなバイオテクノロジー企業や製薬会社のコンサルタントや役員を務め、Repligenの科学諮問委員会の会長を務めています。

Cramer博士はレンセラー工科大学のWilliam Weightman Walker Processorであり、複雑な生物学的産物の分離や、そのバイオマニュファクチャリングを可能にするためのクロマトグラフィー材料、プロセス、予測ツールの開発に貢献したことで知られています。また、このような分離システムにおいてユニークな選択性を生み出す相互作用の分子理解にも多大な貢献をしてきました。現在、彼の研究室では、タンパク質の結合親和性の予測とクロマトグラフィーシステムのマルチスケールモデリング、効率的な抗体およびバイスペシフィック抗体分離システムの開発、マルチモーダルクロマトグラフィーの基礎研究、親和性ペプチド設計のためのマルチレベル自動ペプチド合成/スクリーニングシステム、スマートバイオポリマー親和性沈殿システム、タンパク質と表面、リガンドおよびタンパク質との相互作用の生物物理学、プロセスHCPの効果的な除去のためのプラットフォーム戦略、統合された半連続バイオマニュファクチャリングプロセスなど、タンパク質と表面の相互作用に関連するいくつかの分野の研究を行っています。『Separation Science and Technology』誌の編集者を20年間務め、Alan S. Michaels Award for the Recovery of Biological Products（ACS Division of Biochemical Technology）、ACS National Award in Separation Science and Technologyを受賞しています。また、レンセラー工科大学の優秀教員賞、工学部優秀教授賞、研究優秀賞も受賞しています。Cramer博士は、米国科学振興協会、米国化学技術者協会、米国化学会、米国医学生物工学研究所のフェローに選出されています。 

Alfred Goldberg is a Professor of Cell Biology at Harvard Medical School. His research has concerned the mechanisms and regulation of protein breakdown in cells. His laboratory first demonstrated the existence of the non-lysosomal pathway for protein breakdown (now termed the ubiquitin-proteasome pathway), the 26S proteasome, and the ATP-dependent proteases responsible for protein degradation in bacteria. He also initiated the development of the proteasome inhibitor, Bortezomib/Velcade, now used worldwide for the treatment of multiple myeloma. His research accomplishments have been recognized with many honors, including three honorary degrees, the Gordon Alpert Prize, the Ernst Beutler Prize, and the 2021 Passano Award for Medical Research. He has been elected to the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts & Sciences, and he is among the 0.01% most cited authors in the life sciences. Dr. Goldberg has served frequently as a consultant to biotech companies and for 7 years served on the Board of Directors of Repligen. 

Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

J. Christopher Loveは化学工学におけるRaymond A.（1921）and Helen E. St. Laurent Professorであり、MITのコッホ研究所の統合的癌研究のメンバーでもあります。また、Eli and Edythe L. Broad Institute、およびRagon Institute of MGH, MIT and Harvardのアソシエイトメンバーでもあります。Love教授は、2004年にハーバード大学で物理化学の博士号を取得しました。2004年から2005年までハーバード大学医学部、2005年から2007年まで免疫疾患研究所で免疫学の研究を広げました。彼の研究の中心は、慢性的なヒト疾患の臨床サンプルから細胞をモニターするためのシンプルなマイクロシステムの使用と、生物学的製剤やワクチンを効率的かつ安価に製造するための新しいアプローチの開発です。Love教授は、2009年にはDana Scholar for Human ImmunologyとKeck Distinguished Young Scholar in Medical Researchに選ばれ、2010年には『Popular Science』誌のBrilliant 10の1人に選ばれ、さらにCamille Dreyfus Teacher-Solarにも選ばれました。MITでは、バイオ医薬品やワクチンの新しい製造ホストを推進する、ユニークなMITと業界のパートナーシップであるオルタナティブホストコンソーシアムのディレクターを務めています。以前は、Biogen社のDistinguished Engineer in Residence（2015～2016年）を務めていました。また、MITでの彼の研究室の技術を基にした3つの新興企業（Honeycomb社、OneCyte社、Sunflower社）を含む、複数のバイオテクノロジーおよびバイオ医薬品企業のコンサルティングも行っています。